Enlaces Directos
¿Qué es la fibrosis pulmonar idiopática?
- “Fibrosis” se refiere a la cicatrización
- “Pulmonar” se refiere a los pulmones
- “Idiopática” significa que se desconoce su causa
La fibrosis pulmonar idiopática es la cicatrización del tejido de los pulmones
- Esta cicatrización, o fibrosis, podría ser resultado de pequeñas lesiones en lo profundo de los pulmones que no cicatrizan correctamente
- Estas lesiones provocan la cicatrización progresiva del tejido de los sacos de aire (denominados alvéolos). Esta cicatrización, o fibrosis, hace que los pulmones se endurezcan
- La fibrosis podría dañar la capacidad de los pulmones para intercambiar gases como el oxígeno con la sangre
- La fibrosis pulmonar idiopática es progresiva. Esto significa que, con el tiempo, la cicatrización se extiende aún más y se reduce la función pulmonar
- La fibrosis pulmonar idiopática avanza rápidamente en el caso de algunas personas y lentamente en el de otras. El objetivo del tratamiento es ayudar a que la progresión de la enfermedad sea más lenta
¿Qué es Esbriet® (pirfenidona)?
Esbriet (pronunciado es-BRI-et) es un medicamento de venta con receta aprobado por la Administración de Alimentos y Medicamentos (Food and Drug Administration, FDA) para el tratamiento de la fibrosis pulmonar idiopática.
- Una vez que comience a tomar Esbriet, podría no “sentirse” diferente porque Esbriet no trata los síntomas de la fibrosis pulmonar idiopática ni reversa el tejido cicatrizado de los pulmones
- La FDA aprobó Esbriet en los Estados Unidos en 2014
- Esbriet está específicamente estudiado y aprobado para su uso en la fibrosis pulmonar idiopática, que es un cierto tipo de enfermedad pulmonar intersticial (EPI)
- La fibrosis pulmonar idiopática es diferente de otras EPI o enfermedades que causan inflamación o cicatrización de los pulmones
Un consejo para mantenerse positivo de parte de una Embajadora de Esbriet
“Los animo a que se enfoquen a ser una luz para otros en este mundo. La fibrosis pulmonar idiopática puede no haber estado en nuestros planes, pero juntos podemos usar nuestras experiencias para ayudarnos unos a otros en este difícil camino.”
Socorro
Embajadora de Esbriet
-
-
Genentech’s educators are called Clinical Education Managers. They do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your health care provider.
Genentech’s educators are called Clinical Education Managers. They do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your health care provider.
-
Zitter Health Insights. Policy & Access Tracking Tool for Idiopathic Pulmonary Fibrosis. Published September 2017.
Zitter Health Insights. Policy & Access Tracking Tool for Idiopathic Pulmonary Fibrosis. Published September 2017.
-
Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
-
The Medicare Extra Help program is not a Genentech program. It is administered by the Social Security Administration. The co-pay amount for Medicare Extra Help changes each year.
The Medicare Extra Help program is not a Genentech program. It is administered by the Social Security Administration. The co-pay amount for Medicare Extra Help changes each year.
-
This Esbriet $5 Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit EsbrietCopay.com for the full list of Terms and Conditions.
This Esbriet $5 Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit EsbrietCopay.com for the full list of Terms and Conditions.
-
To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Esbriet $5 Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Esbriet $5 Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
-
Eligible patients will pay as little as $5 per valid prescription, subject to a maximum benefit of $25,000 for a 12-month period.
Eligible patients will pay as little as $5 per valid prescription, subject to a maximum benefit of $25,000 for a 12-month period.
-
-